In addition, CXCR4 has been found to be associated with tumor drug resistance [40–41], and Gao DY et al. found the clinical potential of CXCR4-targeted NPs for delivering sorafenib and overcoming acquired drug resistance in liver cancer [42] which suggesting that CXCR4 may be associated with anti-angiogenic drug resistance. This evidence concerns the gene CXCR4 and neoplasm.